Medical Oncologist
Biomarker & Molecular Testing
Liquid Biopsy vs Tissue Biopsy: — Which Test Do You Need?
Both tests look for cancer biomarkers, but they work differently and suit different situations. Understanding the difference helps you ask the right questions at your next appointment.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- Tissue is still the standard — For initial diagnosis and full biomarker profiling, tissue biopsy remains the reference test in most guidelines.
- Liquid biopsy is a blood draw — No surgical procedure is needed — a blood sample is enough for the laboratory to analyse circulating tumour DNA.
- One does not replace the other — Liquid biopsy is an additional tool, used alongside or after tissue testing, not instead of it in most situations.
- The right answer depends on your situation — Your oncologist decides based on your cancer type, what has already been tested, and what the result needs to inform.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Your oncologist is likely to recommend tissue biopsy first, because it remains the gold standard for diagnosis and gives the most complete picture of your tumour's biology. Liquid biopsy — a blood test — is used when getting more tissue is difficult, or to track how your cancer is responding to treatment.
Which test does your situation call for?
Tissue biopsy is the standard first test for most cancer diagnoses. Your surgeon or radiologist takes a sample directly from the tumour, and the laboratory analyses its DNA and protein markers to confirm the cancer type and identify the biomarkers that guide treatment.
Liquid biopsy analyses fragments of tumour DNA that shed into the bloodstream — called circulating tumour DNA, or ctDNA. It requires only a blood draw. ESMO and NCCN guidance recognises liquid biopsy for specific situations: when a tumour is hard to reach, when the tissue sample was insufficient, or when re-testing is needed during or after treatment.
In a proportion of patients, both tests are used. Tissue biopsy establishes the diagnosis; liquid biopsy is used later to track whether resistance mutations have appeared or how the cancer is responding.
When is liquid biopsy more likely to be offered?
- Your tumour is in a location where repeat biopsy carries significant risk, such as a lesion near a major blood vessel or deep in the chest.
- The original tissue sample was too small for full biomarker testing and obtaining more tissue is not straightforward.
- You have been on targeted therapy for some months and your oncologist wants to check whether resistance mutations have developed.
- You need a result to inform an urgent treatment decision and a blood test can answer the specific question being asked.
- You are being monitored after surgery or chemotherapy for signs that cancer cells are still present at low levels.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
How do liquid biopsy and tissue biopsy compare?
| Tissue biopsy | Liquid biopsy | |
|---|---|---|
| What is tested | A sample taken directly from the tumour | Circulating tumour DNA shed into the blood |
| How it is collected | Needle, endoscope, or surgical procedure | Blood draw — no tissue procedure needed |
| Primary use | Initial diagnosis; full molecular profile | Monitoring; re-testing; hard-to-access tumours |
| Turnaround | Longer — tissue must be processed before sequencing | Generally faster — no tissue processing step |
| What it can miss | Changes that have occurred in the tumour since the original sample | Mutations present in the tumour but not yet shed into blood in detectable quantities |
| Cost (indicative) | Varies widely by panel; ask your centre for the current figure | Generally higher than standard tissue panels; ask the laboratory directly |
What if the liquid biopsy comes back negative?
A negative liquid biopsy does not rule out a mutation. Some tumours shed very little DNA into the bloodstream, and a low-shedding tumour may not appear on a blood test even when the mutation is present in the tissue.
ESMO guidance is explicit on this point: a negative liquid biopsy result should prompt tissue re-biopsy rather than a conclusion that the mutation is absent. Your oncologist will tell you whether the result changes your plan or whether tissue testing is needed to confirm.
What else do patients ask about these tests?
Can I ask for liquid biopsy instead of a tissue biopsy?
You can ask, and it is a reasonable question. But your oncologist may decline for a good reason: a negative liquid biopsy in someone who has not yet had tissue testing does not confirm that a mutation is absent. Tissue biopsy remains more sensitive for initial diagnosis, and most oncology guidelines still require it as the first step before treatment decisions are made on biomarker results.
Why is my oncologist asking for another biopsy when I already had one?
Cancer changes over time, particularly during or after treatment. A mutation that was absent at diagnosis can appear later — often when the cancer develops resistance to a targeted therapy. The repeat biopsy is checking today's biology, not re-confirming the original diagnosis. In some situations a liquid biopsy can answer this question instead, but tissue gives a more complete picture of the specific resistance mechanism that has developed.
Is liquid biopsy covered by insurance in India?
Coverage varies by insurer and by policy. Some insurers cover it when ordered by an oncologist as part of a documented treatment decision; others do not. Ask your insurance desk before the test is booked, and ask your oncology team to document the clinical reason clearly — a written indication from your oncologist improves the likelihood of approval. Costs have changed considerably over recent years, so ask the laboratory directly for the current figure rather than relying on any figure you have seen online.
For lung cancer, is liquid biopsy good enough to replace tissue testing?
NCCN and ESMO both accept liquid biopsy for EGFR mutation testing in lung cancer when tissue is insufficient or re-biopsy carries significant risk. However, liquid biopsy misses a meaningful proportion of patients who would test positive on tissue. If the blood test is negative, tissue testing is still recommended. Your oncologist will decide which sequence is right for your specific situation, including which mutations need to be looked for given your treatment history.
What happens when tissue and liquid biopsy give different results?
When the two tests disagree, the tissue result is generally treated as more reliable for the specific mutation it was designed to detect — because tissue directly samples the tumour rather than the DNA it sheds. Your oncologist will weigh both results alongside your imaging and clinical picture. Discordant results sometimes mean a second opinion on the pathology or a discussion at a multidisciplinary tumour board is the right next step before a treatment decision is made.
How do I know if the laboratory doing my liquid biopsy is reliable?
Ask whether the laboratory is NABL-accredited and whether it uses a validated next-generation sequencing platform. Ask how many liquid biopsy tests it processes each month — higher volume generally correlates with more consistent performance. A reliable laboratory will report its detection limit and include a quality control section in its report. This is the standard that ASCO and ESMO guidance expects for clinical ctDNA testing used to inform treatment decisions.
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
How long do liquid biopsy and tissue biopsy results take?
Liquid biopsy results are generally available faster than tissue biopsy results, because a blood sample requires no tissue processing before sequencing begins. Tissue biopsy — especially when a full next-generation sequencing panel is run — takes longer because the sample must be prepared, embedded, and sequenced. Both timelines vary by laboratory and by the specific panel being run. Ask the laboratory processing your sample when you should expect the result, so you are not waiting without a clear timeline.
How much does liquid biopsy cost in India?
Costs vary by laboratory, by the number of genes being tested, and by the platform being used — figures change frequently and differ across cities. Any number quoted online may not reflect what your centre charges today. Ask the laboratory directly for the current cost of the specific panel your oncologist has ordered. If cost is a concern, tell your oncologist — there may be options, including government schemes that cover some biomarker testing depending on your cancer type and situation.
Can liquid biopsy detect all cancer mutations?
No. Liquid biopsy detects mutations that are shed into the bloodstream in sufficient quantities to be measured. Some tumours shed very little DNA regardless of stage, making them difficult to detect on a blood test. This is why a negative liquid biopsy result does not mean a mutation is absent — it means it was not detectable in the blood at that moment. Tissue biopsy has higher sensitivity for most mutations in the initial diagnostic setting, which is why it remains the standard first step.
Is liquid biopsy painful?
No. Liquid biopsy requires only a blood draw, the same as a routine blood test. There is no needle into the tumour, no sedation, and no recovery time. This is one of the reasons it is preferred when re-testing is needed during treatment — you do not need another invasive procedure, and the result can generally be turned around faster than a repeat tissue sample.
What is ctDNA and why does it matter for my treatment?
ctDNA stands for circulating tumour DNA — fragments of genetic material that cancer cells shed into the bloodstream as they divide or die. Analysing ctDNA can reveal the mutations driving your cancer's growth, whether those mutations are changing under treatment pressure, and in some cancers, whether cancer cells are still present at low levels after surgery. This information helps your oncologist decide whether to continue the current treatment, switch to a different targeted therapy, or watch closely for early signs of recurrence.
Will CION coordinate my biopsy testing?
Yes. Biomarker testing — including liquid biopsy and tissue next-generation sequencing panels — is coordinated through your oncologist at CION as part of the treatment planning process, and samples are sent to accredited laboratories for processing. PET-CT and other response-assessment imaging are coordinated with partner imaging centres. If you have questions about which tests have been ordered or what the results mean, ask at your next appointment — a written summary of your biomarker results is a reasonable thing to request.